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ABSTRACT 
BACKGROUND:    Discontinuation of tyrosine kinase inhibitor (TKI) therapy is feasible for 
some patients with chronic myeloid leukaemia (CML) with deep molecular responses, 
defined as stable MR4 (BCR-ABL1/ABL1 ratio <0.01%). However, patients in stable major 
molecular response (MMR; MR3; BCR-ABL1/ABL1 ratio consistently < 0.1%) but not MR4 
have not hitherto been studied. In addition, the effect of treatment de-escalation rather than 
outright stopping has not been investigated so far. 
PATIENTS and METHODS:  This study recruited 174 British adult CML patients in first 
chronic phase who had received TKI for ≥3 years and were either in stable MR4 (the ‘MR4 
cohort’ n=125) or in stable MMR but not MR4 (the ‘MMR cohort’; n=49) for ≥12 months. 
Participants received half their standard TKI dose for 12 months. Molecular recurrence was 
defined as loss of MMR (>0.1%) on two consecutive samples. The study endpoint is the 
proportion of patients who lose their MMR on de-escalation and regain MMR on TKI 
resumption. The trial was registered at https://clinicaltrials.gov/ as NCT 01804985. 
FINDINGS:  During the 12 months of half-dose therapy, 12 patients had molecular 
recurrence, all of whom regained MMR within 4 months of full dose TKI resumption. 
Recurrence was lower in the MR4 cohort (3 of 121 evaluable patients; 2.5%, 90% CI: 0.2-
4.8%) than in the MMR cohort (9 of 48 evaluable patients; 18.8%, 90% CI: 9.5-28%) (p = 
0.0007), but was unrelated to prior TKI or TKI therapy duration. Many adverse events 
improved during the first 3 months of de-escalation, though not thereafter. Overall, de-
escalation saved 46.7% from an expected TKI budget (without de-escalation) of £4,156,969.  
INTERPRETATION: TKI de-escalation is safe for the vast majority of patients with 
excellent responses to TKI therapy, and is associated with improvement in symptoms and 
significant financial savings. The data imply that lower TKI doses may maintain responses in 
these patients. 
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INTRODUCTION 
The advent of daily tyrosine kinase inhibitor (TKI) therapy for chronic myeloid leukaemia 
(CML) has transformed the outlook for CML to a disease where the majority of patients can 
expect a normal life span.1 However, TKI therapy is not without adverse effects2 and is 
expensive3. This has led to CML specialists and patients asking whether after a few years of 
TKI therapy, the disease may be sufficiently suppressed to permit treatment discontinuation. 
Several studies have established that some patients with enduring deep molecular responses 
to TKI therapy can discontinue treatment (reviewed in4,5). Early studies were confined to 
patients with undetectable BCR-ABL1 transcripts by standard reverse transcriptase 
polymerase chain reaction (RT-PCR), and defined molecular recurrence as the reappearance 
of BCR-ABL1 transcript positivity6,7. More recent studies have specified recurrence as the 
loss of major molecular response (MMR, defined as BCR-ABL1/ABL1 transcript ratio of  
>0.1%, also called MR3 [molecular response of 3 logs below an arbitrary standard baseline]). 
Using this definition of recurrence, at 24 months after TKI cessation the A-STIM and KIDS 
studies reported that 58-64% of patients are recurrence-free8, 9 and the large EUROSKI study 
of 868 patients similarly recently reported a rate of 52% at the same time point10. 
However, these studies were confined to patients in stable MR4 at entry, i.e. whose BCR-
ABL1/ABL1 ratio is consistently below 0.01% (molecular response 4 logs below the standard 
arbitrary baseline). Although there are anecdotal reports of successful treatment cessation for 
a few months in patients in stable MMR but not MR4, e.g. during pregnancy11, such patients 
have not hitherto been formally studied in a stopping trial. In addition, TKI dose reduction in 
patients with good responses to TKI therapy but also troublesome adverse events can 
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ameliorate these yet maintain deep molecular response2. We therefore questioned whether 
some patients who might experience molecular recurrence on stopping TKI might 
nevertheless have been able to safely decrease TKI treatment without an increase in tumour 
burden. 
The present De-Escalation and Stopping Therapy with Imatinib, Nilotinib or sprYcel 
(DESTINY) study was designed to examine the effects of treatment de-escalation as a 
prelude to complete cessation, in patients not only with deep molecular responses of MR4 or 
greater, but also to include patients with MMR but not MR4. The cessation phase is ongoing; 
here we report that de-escalation is safe for the vast majority of patients and that it is 
associated with a decrease in the severity of adverse events and significant savings in TKI 
costs. 
 
 
PATIENTS and METHODS 
Entry/exclusion criteria 
Trial entry was restricted to BCR-ABL1 transcript positive patients with either an e13a2, 
e14a2 or e19a2 fusion transcript, aged 18 or over in first chronic phase of CML, who had 
either received the same TKI (imatinib, dasatinib or nilotinib) since diagnosis or had switched 
only once for intolerance to the initial drug. Patients who showed resistance to prior TKIs and 
switched to another TKI were excluded. Prior interferon treatment was not an exclusion 
criterion as long as it had finished at least 12 months before entry; Philadelphia chromosome 
positivity was not mandatory. Participants must have received TKI for at least 3 years, and all 
PCR tests (minimum of 3) in the 12 months before trial entry must have been ≤0.1% (i.e. 
MMR), each with ≥ 10,000 ABL1 control transcripts. Patients who had previously received 
more than 400mg daily of imatinib or 100mg daily of dasatinib or 400mg twice daily of 
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nilotinib were ineligible unless their high dose arose from participation in an earlier clinical 
trial in which higher doses were being compared with standard doses. Recipients of bosutinib 
or ponatinib at any point were ineligible. All entrants provided informed consent, and the trial 
was carried out in line with the Declaration of Helsinki, sponsored jointly by the University 
of Liverpool and Royal Liverpool & Broadgreen University Hospitals Trust, and they and the 
funding sources had no role in study design, or collection, analysis, or interpretation of the 
data or in the writing of this manuscript. Ethical approval was granted by the North West - 
Liverpool East Committee of the UK National Research Ethics Service. The trial was 
registered at https://clinicaltrials.gov/ as NCT 01804985. 
 
Trial design 
Participants decreased their entry TKI to half the standard dose for 12 months, as follows: 
imatinib 200mg daily, dasatinib 50mg daily or nilotinib 200mg twice daily. Central 
monitoring was carried out monthly in a central laboratory at Imperial Molecular Pathology 
at Hammersmith Hospital, London, and all BCR-ABL1 ratios were expressed according to 
International Scale. Any result > 0.1% prompted an urgent ‘alert’ to the site to request a 
further confirmatory sample, typically carried out within 2 weeks of the alerting sample. 
Molecular recurrence was defined as loss of MR3 (>0.1%) on these two consecutive samples 
and timed as the date of the first of these samples. In the event of recurrence, all patients were 
required to resume the standard dose of their entry TKI. Molecular monitoring continued 
monthly until MMR was reached again. The study endpoint is the proportion of patients who 
lose their MMR on de-escalation and regain MMR on TKI resumption. 
Formal adverse event reporting was not attempted, though the presence and severity of TKI 
related symptoms were recorded at each monthly visit, both by verbal reporting and by the 
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formal quality of life instruments EQ-5D12 and FACT-BRM13. In addition each patient was 
asked to complete a diary of symptoms arising between scheduled visits. 
 
Sample size and statistical analysis 
The trial was originally structured as 2 parallel cohorts, one comprising patients who were in 
MR4 for all assessments in the 12 months prior to entry, and the other for patients who were 
partially or wholly in MMR but not stable MR4 during this time. Since the latter cohort could 
be regarded as more experimental, this arrangement provided a mechanism for the independent 
Data Monitoring Committee to close that arm if its recurrence rate was unacceptably high, 
without prejudicing the MR4 cohort. The minimum required sample size (168) was calculated 
on the basis of the maximum width of the 90% confidence interval for a wide range of values 
of the proportion of relapsing patients; we required the maximum width for the smallest group 
to be smaller than 0.28. 
Authors REC (corresponding author), FP and TC had full access to all of the data, and LF 
had access to the molecular data. Authors REC and FP had the final responsibility to submit 
for publication. All statistical analyses were performed on an intention to treat basis using the 
R Programming Language for Statistical Analyses, version 3.3.1. No adjustment for multiple 
testing or missing data was incorporated. The proportions of patients relapsing were 
estimated together with 90% confidence intervals. Survival distribution curves were 
estimated by the method of Kaplan and Meier. Five patients (3 imatinib, 1 each for nilotinib 
and dasatinib) were already on the half-dose at trial entry because of toxicity at 
standard/intermediate doses (their entry was not excluded in the protocol). These patients all 
continued on half-dose treatment and are included in all the analyses. 
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In the calculation of TKI drug costs, the UK National Health Service list price for each TKI 
dose was used, without any local discounts and without Value Added Tax (20% currently in 
the UK).  
 
 
RESULTS 
Between 16th December 2013 and 10th April 2015, 174 patients (male 98; female 76) were 
recruited after giving informed consent from 20 UK centres. Their flow through the trial is 
summarised in the CONSORT diagram in Figure 1. Of these, 125 fulfilled the definition for 
the MR4 cohort and 49 fell into the definition of ‘MMR but not MR4’ (hereafter referred to 
as ‘the MMR cohort’) as defined above. At entry, 148 patients were receiving imatinib, 16 
nilotinib and 10 dasatinib.  Details for the study population are given in Table 1. The median 
duration of TKI therapy was 7.7 and 6.5 years for the MMR and MR4 cohorts respectively 
though this was not significantly different; otherwise the MMR and MR4 cohorts were 
broadly comparable.  
 
Effect of de-escalation on molecular recurrence 
During the 12 months of half-dose therapy, 12 patients had molecular recurrence (loss of 
MMR), all of whom were receiving imatinib. Molecular recurrence was significantly lower in 
the MR4 cohort (3 of 121 evaluable patients; 2.5%, 90% CI: 0.2-4.8%) than in the MMR 
cohort (9 of 48 evaluable patients; 18.8%, 90% CI: 9.5-28%) (p = 0.0007). The median time 
to relapse was shorter in the MMR cohort than in the MR4 cohort (4.4 months vs. 8.7 
months), as shown in Figure 2 panel A. As shown in Table 2, the probability of molecular 
recurrence on de-escalation was not related to age, gender, weight, performance status, BCR-
ABL1 transcript type, or the duration of TKI therapy (median 6.9 years overall). In this 
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regard, no recurrences were observed in the quartile with the shortest  prior TKI treatment (< 
4.8 years), compared with 5/43 in the 2nd quartile (4.8-6.9 years),  4/43 in the 3rd quartile (6.9-
10.2 years) and 3/44 in the 4th quartile (10.2-14.1 years). Too few data were available from 
diagnosis on the components (especially spleen size) of the Sokal, EURO/Hasford or more 
recent scoring systems to investigate whether these might predict molecular recurrence. Too 
few patients were receiving dasatinib or nilotinib to allow comparison of recurrence rates 
between imatinib and second generation TKI recipients. In addition, the probability of 
molecular recurrence was not related to simple blood count parameters (data not shown). Five 
patients (1 MMR and 4 MR4) did not complete 12 months of de-escalation for various 
reasons (poor protocol adherence (2 patients), relocation, pregnancy and intercurrent illness). 
Table 4 shows that 22 patients entered the trial on lower than usual TKI doses. Two 
recurrences occurred among the 18 patients taking less than imatinib 400mg daily (11.1%), 
which is comparable to the 10 recurrences among 130 patients (7.7%) entering on 400mg 
daily. We cannot comment on the effect of lower entrance doses for dasatinib (2 cases) or 
nilotinib (2 cases) as no 2G TKI recipient had molecular recurrence. 
No progression to advanced phase or loss of cytogenetic response was seen. No tyrosine 
kinase domain mutation was detected at the time of molecular relapse in any of 7 patients 
analysed to date by next generation sequencing. As shown in Figure 2 panel B, all 12 patients 
with molecular recurrence regained MMR within 4 months of resumption of full dose TKI 
(median time to recovery = 77 days). As shown in the CONSORT diagram of Figure 1, 36 
(73%) patients in the MMR cohort and 117 (94%) in the MR4 cohort have proceeded to the 
currently ongoing stopping phase of the trial. 
 
Effect of de-escalation on adverse events 
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Many patients described symptoms present at trial entry, either in verbal reporting at 
scheduled visits or in their diaries. In the first 3 months of de-escalation, many of these 
improved as shown in Figure 3. However, little further improvement was seen in the 
subsequent ~9 months. Details of symptoms that were not present at trial entry that arose 
during de-escalation are given in the Supplementary Table. Fifty-three new musculoskeletal 
symptoms were reported by 36 patients (21%), of which 43 were assessed as grade 1 (not 
interfering with the patient's usual function), and 10 as grade 2 (enough discomfort to 
interfere with usual activity). The episodes were described as cramps, arthritis or 
musculoskeletal pain. No grade 3 or 4 episodes were recorded. A similar pattern, albeit at 
lower frequency, was also observed for other common TKI adverse events, summarised in 
the Supplementary Table. Interestingly, all 12 recurrences occurred in the 138 patients that 
did not report any musculoskeletal withdrawal symptoms (i.e. recurrence rate of 8.7%).  
During the course of the trial, 15 serious adverse events were reported, summarised in Table 
3. All were assessed by sites as unrelated to the TKI or the underlying CML. They included 
one fatality due to worsening pre-existing peripheral arterial occlusive disease in a patient 
who had received only imatinib. 
Formal quality of life assessments by EQ-5D and FACT-BRM were of marginal use as the 
mean scores for each instrument were similar to that of a healthy control population at trial 
entry and did not appreciably change during de-escalation (data not shown). 
 
Financial effect of de-escalation 
Table 4 gives details of the savings in drug costs during the 12 months of de-escalation. 
Figures are in UK pounds sterling throughout. In the UK, although the cost of imatinib is 
directly proportional to the dose used, this is not the case for nilotinib (400mg twice daily and 
300mg twice daily cost the same) or dasatinib (100mg daily and 80mg daily cost the same). 
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Among the 12 patients undergoing molecular recurrence, the timing of relapse and of the 
subsequent resumption of standard TKI dose was variable, resulting in saved TKI costs 
varying from £3,038 to £12,311 per relapsing patient. Overall, 46.7% (£1,943,364) was saved 
from an expected TKI budget (without de-escalation) of £4,156,969. If considering the MR4 
cohort alone, the saving was 47.7% (£1,429,330 from an expected budget of £2,993,854). 
Similarly, in the MMR cohort alone, the saving was 44.2% (£514,034 from an expected 
budget of £1,163,115). 
 
DISCUSSION 
Although several studies of TKI cessation have been reported, almost nothing is known about 
the feasibility of treatment de-escalation in patients with stable molecular responses. A 
single-arm study commenced in 2008 of 76 patients aged 65 years or older who had received 
imatinib for at least 2 years and in stable complete cytogenetic response (for at least 1 year) 
examined intermittent imatinib (1 month on alternating with 1 month off). Almost all entrants 
were in fact also in MMR. With a minimum follow-up of 4 years, 27 patients (35%) lost 
MMR (and 13 (17%) lost cytogenetic remission)14, though all patients with adequate follow 
up regained MMR within 7 months. In the present study, we demonstrate 3 principal 
findings. Firstly, with a molecular recurrence rate of 2.5% after 12 months, de-escalation is 
clearly safe for patients in stable MR4 or deeper remission. Similarly, since 81% of patients 
in stable MR3 though not MR4 remain recurrence-free at 12 months, it is also clinically 
reasonable to offer de-escalation to such patients. It has been suggested that the absence of 
stable MR4 should be a ‘red light’ warning against treatment cessation4. The present report is 
confined to treatment de-escalation so does not allow comment on this, but does suggest that 
as long as the patient is in stable MMR, de-escalation may be a reasonable option. Also, our 
findings cannot be generalised to patients with excellent responses to a TKI given as second 
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line after initial resistance, since these patients were excluded here. It is of interest that all 12 
patients experiencing molecular recurrence were among the 148 receiving imatinib, while no 
recurrences were seen in the recipients of second generation TKI; this difference was not 
statistically significant. Since all relapsing patients promptly returned to MMR or better 
within 4 months of resumption of full TKI dose, it is plausible that de-escalation should 
become the standard of care for such patients.  
Secondly, this practice-changing view is reinforced by the demonstration of general 
improvement of adverse events in both the MMR and MR4 cohorts, with only mild (none > 
grade 2 severity) and transient evidence of the musculoskeletal symptoms that have recently 
been described on complete TKI withdrawal9,15. Although these and other symptoms 
generally improved during de-escalation as shown in Figure 3, this trend was not of sufficient 
strength to be detectable by the quality of life assessment tools used here, emphasising their 
inappropriateness for well controlled CML patients in the TKI era16,17. Quality of life data 
using a symptom assessment tool more dedicated to TKI-treated CML patients18,19 would be 
of interest in future studies of TKI de-escalation/discontinuation. Although the trial protocol 
required patients with molecular recurrence to resume their TKI at full dose until MMR was 
re-attained, it would be interesting to formally study whether it is possible to subsequently 
resume reduced-dose treatment without molecular recurrence.  
Thirdly, de-escalation in the MR4 cohort alone, the MMR cohort alone or the combined 
population is associated with a saving of almost half their expected TKI costs. The exact 
magnitude of these savings is dependent on local base prices, including any taxes, and for 
imatinib these are currently falling as generic alternatives are introduced. Although we have 
used individual patient TKI consumption data, it does not take account of the increased PCR 
monitoring and associated clinical visits that are advisable in patients undergoing de-
escalation (or complete cessation). These appear very unlikely to significantly impact on the 
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impressive savings on TKI costs, though require further study in trials incorporating detailed 
pharmaco-economic evaluation of TKI de-escalation/cessation. 
In summary, in CML patients with stable MR3 or better, decreasing TKI treatment to half the 
standard dose appears safe, and is associated with improvement in TKI related side effects, 
implying that many patients with stable responses may be able to maintain their responses on 
lower TKI doses. De-escalation is also associated with substantial financial savings. Studies 
of more ambitious de-escalation are warranted. 
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TABLE and FIGURE LEGENDS  
Table 1. Patient characteristics at trial entry. IQR = interquartile range. BCR-ABL1 data are the 
centralised results at trial entry. 
 
Table 2. Effect of various parameters on molecular recurrence.  Data are frequency 
(proportion) for categorical variables, and median (IQR) for continuous variables. Statistical 
tests are Fisher’s exact test for categorical variables and the Mann-Whitney U-test for 
continuous variables. 
 
Table 3. Serious adverse events during de-escalation. SAE = serious adverse event. Data are 
the number of SAEs (number of patients). Grading is according to the National Cancer 
Institute Common Toxicity criteria. * denotes the single fatality. 
 
Table 4. Financial implications of de-escalation. All costs are in pounds sterling using the UK 
National Health Service list price, exclusive of Value Added Tax. Costs for imatinib are for 
commercial Glivec®. UPN = unique patient number. 
 
Figure 1. CONSORT diagram of patient disposition during de-escalation. 
 
Figure 2. Molecular recurrence-free survival (panel A) and time to re-attaining MMR (panel 
B), for the MMR and the MR4 cohorts. Numbers at risk are as stated. The hazard ratio for the 
difference in recurrence free survival between the two groups is 0.12 (90% Confidence Interval 
= 0.04 – 0.37). 
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Figure 3.  Evolution of patient-reported symptoms by month, for the MMR (left panel) and 
MR4 (right panel) cohorts.  
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Table 1. Patient characteristics at trial entry. 
 
 MMR 
N = 49 
MR4 
N = 125 
Overall 
N = 174 
Demographic Characteristics 
Age 
median (IQR)  
57  
(45, 66) 
61  
(51, 68) 
59  
(50, 68) 
Gender  
Male [n (%)] 
25 (51%) 73 (58%) 98 (56%) 
Physical findings 
Weight  
median (IQR) 
Missing 
79 
(70, 89) 
1 
81 
(72, 94) 
- 
81 
(72, 92) 
1 
ECOG performance status [n, (%)] 
0 - Fully Active 
1 - Work Able 
2 - Not Work Able 
3 - Limited Self Care 
4 - Completely Disabled 
 
42 (86%) 
7 (14%) 
- 
- 
- 
 
113 (90%) 
10 (8%) 
1 (1%) 
1 (1%) 
- 
 
155 (89%) 
17 (9%) 
1 (1%) 
1 (1%) 
- 
Clinical characteristics  
BCR-ABL1/ABL1 transcript ratio (%) 
median (IQR, range) 
0.0047 
(0.002, 
0.009) 
0.001 
(0.0003, 0.002) 
0.001 
(0.0006, 0.003) 
Medical History 
Total time on TKI (years) 
median (IQR) 
Missing 
7.7  
(5.1, 10.7) 
- 
6.5  
(4.8, 10.2) 
1 
6.9  
(4.8, 10.2) 
1 
Medication 
Imatinib [n (%)] 43 (88%) 105 (84%) 148 (85%) 
Nilotinib [n (%)] 2 (4%) 14 (11%) 16 (9%) 
Dasatinib [n (%)] 4 (8%) 6 (5%) 10 (6%) 
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Table 2. Effect of various parameters on molecular recurrence. 
 
Characteristic 
Molecular Recurrence 
p-value Yes 
(n = 12) 
No 
(n = 162) 
    Molecular cohort    
MMR 9 (75%) 40 (25%) 0.0007 
MR4 3 (25%) 122 (75%) 
Gender    
Male 6 (50%) 92 (57%) 0.77 
Female 6 (50%) 70 (43%)  
ECOG performance status    
0 12 (100%) 143 (88%) 0.37 
1+ 0 (0%) 19 (12%)  
    
    
    
        Age 60 (46, 69) 59 (50, 68) 0.84 
    Weight (kg) 84 (74, 90) 80 (71, 92) 0.90 
    Time on TKI (years) 7.6 (6.4, 9.1) 6.8 (4.8, 10.2) 0.36 
    Time in MMR (years) 5.1 (4.4, 6.6) 5.5 (3.8, 8.4) 0.68 
Missing - 1  
    
BCR-ABL1 transcript type    
e13a2 5 (42%) 29 (22%) 0.28 
e14a2 5 (42%) 72 (55%)  
Other/both 2 (16%) 31 (24%)  
    Unknown - 30  
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Table 3. Serious adverse events during de-escalation. 
 
  Grade 
Name (number) of SAE 
Treatment 
cohort 
1 2 3 4 5 
Myocardial infarction (2), 
Syncope (1) 
MMR - - - - - 
MR4 - 1 (1) 2 (2) - - 
Abdominal pain (1) 
MMR - - - - - 
MR4 - - - 1 (1) - 
Pain in lower limbs* (1) 
MMR - - - - - 
MR4 - - 1 (1) - - 
Gallbladder pain (1) 
MMR - - - - - 
MR4 - - 1 (1) - - 
Allergic reaction (1) 
MMR - - - - - 
MR4 - 1 (1) - - - 
Sepsis (3), 
Urinary tract infection (1), 
Skin Infection (1) 
MMR - - 1 (1) - - 
MR4 - 2 (1) 2 (2) - - 
Bone pain (1), 
Other (1) 
MMR - - - - - 
MR4 - - 2 (2) - - 
Urinary retention (1) 
MMR - - - - - 
MR4 - 1 (1) - - - 
Total 
MMR - - 1 (1) - - 
MR4 - 5 (4) 8 (7) 1 (1) - 
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Table 4. Financial implications of de-escalation. 
 
 
Patients with molecular recurrence: 
UPN At tria l  entry: Cohort TKI cost without de-
escalation 
Months  to 
recurrence 
Tota l  months at 
ha l f dose 
Actual  TKI 
cost (£) 
TKI cost saved 
(£) 
 TKI Dose       
         
8 Imatinib 400mg dai ly MMR 23700 10.2 10.4 13596 10104 
22 Imatinib 300mg dai ly MMR 17775 12.0 13.8 11076 6699 
23 Imatinib 400mg dai ly MMR 23700 8.0 8.3 15643 8058 
44 Imatinib 400mg dai ly MMR 23700 4.1 4.1 19736 3965 
51 Imatinib 400mg dai ly MMR 23700 4.8 5.3 18521 5180 
76 Imatinib 300mg dai ly MMR 17775 4.3 4.3 15697 2078 
79 Imatinib 400mg dai ly MMR 23700 2.5 3.1 20663 3038 
107 Imatinib 400mg dai ly MMR 23700 3.2 3.2 20599 3102 
138 Imatinib 400mg dai ly MMR 23700 5.9 5.9 17913 5788 
28 Imatinib 400mg dai ly MR4 23700 8.6 8.9 15003 8697 
89 Imatinib 400mg dai ly MR4 23700 8.0 8.1 15771 7930 
99 Imatinib 400mg dai ly MR4 23700 12.0 12.6 11390 12311 
 
 
Patients completing 12 months of de-escalation without molecular recurrence: 
No. of patients  At tria l  entry: TKI cost without de-escalation (£) Tota l  TKI cost saved (£) 
 TKI Dose   
     
120 Imatinib 400mg dai ly 2844085 1422064 
1 Imatinib  350mg dai ly 20738 8888 
11 Imatinib 300mg dai ly 195528 65176 
1 Imatinib 250mg dai ly 14813 2962 
3 Imatinib 200mg dai ly 35551 0 
10 Ni lotinib 400mg twice daily 317356 158678 
4 Ni lotinib 300mg twice daily 126942 63471 
1 Ni lotinib 225mg twice daily 23802 7934 
1 Ni lotinib 200mg twice daily 15868 0 
8 Dasatinib 100mg dai ly 243983 121992 
1 Dasatinib 80mg dai ly 30498 15249 
1 Dasatinib 50mg dai ly 15249 0 
21 
 
 
Figure 1. CONSORT diagram of patient disposition during de-escalation. 
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